Clinical TrialsResearch
The active biologics landscape

See where the pipeline is concentrating.

Explore active products and interventions across clinical stages, technology families, diseases, companies, and partnerships.

Current snapshotA10
Early Phase 1240
Phase 11,211
Phase 21,521
Phase 3583

Highest active phase per asset · 65 not assigned

Product Sea · current pipeline

Every product, positioned in context.

Start with the complete product landscape. Then use the structured panels below to compare stages, technologies, emerging approaches, and the organizations active in each area.

The complete product landscape loads as it approaches the screen.
Pipeline composition

How technologies change across clinical stages.

Technology family
Early 1240
Phase 11,211
Phase 21,521
Phase 3583
Not set65
Early-stage concentrationCell therapies

51% of its active products are in Early Phase 1 or Phase 1.

Late-stage representationProtein therapeutics

29% of its active products have reached Phase 3.

Cross-sector development363 products

Non-industry-led products that name an industry collaborator.

Classification gap1,109

Products remain outside a specific technology family and stay visible.

Historical trial starts

Where biological research is gathering momentum.

Compare complete five-year cohorts by disease, reported phase, and industry involvement. This is the first historical view built from the reviewed all-status registry spine.

23,919Phase 1–3 biological trials in the historical census
Loading reviewed cohorts…
3,620active products
—lead sponsor organizations
—product–indication links
—products with public evidence
Product registry

Loading the registry…

Definitions and sources

Enough context to read the numbers correctly.

Counts distinguish product groups, source asset records, product–indication links, and trials. Technology labels come from registry descriptions; sourced technical claims retain their original quotations.

  1. 01Count the right unit

    The stage matrix counts each product once at its highest active phase. A separate program lens will count each indication.

  2. 02Keep uncertainty visible

    Unclassified assets and unassigned stages remain in the totals instead of being silently distributed into a category.

  3. 03Open the source record

    Product pages retain registry links and verbatim quotations for public technical claims. Browse the records.